SASB Biotechnology & Pharmaceuticals
SASB
SASB prioritizes sustainability measures for biotech and pharma sectors.
The SASB Biotechnology & Pharmaceuticals costs $0 USD. Renewal costs $0 USD every 12 months.
Key Strengths
- Industry-specific metrics tailored to biotech and pharma materiality
- Widely recognized by institutional investors and ESG rating agencies
- Aligns with IFRS Sustainability Disclosure Standards (ISSB) framework
- Focuses on financially material sustainability topics relevant to capital markets
- Free to access and implement — low barrier to adoption
- Continuously updated through rigorous market feedback and public comment processes
Ideal For
This standard is best suited for publicly traded or investor-facing biotechnology and pharmaceutical companies seeking to align their ESG disclosures with financially material sustainability metrics. It is particularly valuable for sustainability officers, investor relations teams, and CFOs at mid-to-large pharma/biotech firms looking to meet growing investor demand for standardized non-financial reporting.
Target Audiences
Relevant Roles
Industries
Alignment & Recognition
Accrediting Body
Scope
Overview
SASB (Sustainability Accounting Standards Board) establishes standards for corporate sustainability. Specifically for Biotechnology & Pharmaceuticals, SASB focuses on critical areas such as safety of clinical trial participants, ethical marketing, affordability, and drug access.
Founded in 2011, SASB has gained recognition for its pragmatic, transparent approach to integrating sustainability with financial performance. It offers certifications for organizations to ensure they meet these standards. Businesses like Johnson & Johnson, Pfizer, and Merck use SASB standards, enhancing trust and accountability.
SASB's framework helps companies disclose information relevant to investors, promoting investment in sustainable practices. Statistics show that companies adhering to these standards often see improved operational efficiency and risk management. Standards by SASB are continually updated based on market feedback, ensuring they're relevant and effective in addressing current and future issues.
Requirements & Verification
Evidence Requirements
Organizations self-report against SASB's defined disclosure topics and accounting metrics for the Biotechnology & Pharmaceuticals sector. Required disclosures include quantitative metrics (e.g., number of recalls, clinical trial participant safety incidents, percentage of revenue from products in access-to-medicine programs) and qualitative narrative disclosures. No third-party audit is mandated by SASB itself, though companies may choose to have disclosures independently assured.
Prerequisites
Assessment Process
There is no formal exam or audit process for SASB standard adoption. Organizations self-select the relevant industry standard, identify applicable disclosure topics and accounting metrics, and integrate these into their annual sustainability or financial reports. SASB provides implementation guidance and tools (including the SASB Navigator) to support this process. Independent third-party assurance of disclosures is optional and at the organization's discretion.
Renewal & Compliance
SASB standards are not a certification with a formal renewal cycle. Organizations are expected to update their disclosures annually in line with their financial reporting cycle. SASB periodically revises its standards; organizations should monitor updates and adopt revised metrics as they are released.
Accountability Model
Impact & Outcomes
Employer Recognition
Consider Alternatives If...
Organizations primarily seeking operational sustainability certifications (e.g., environmental management systems) rather than investor-focused disclosure frameworks may find SASB less relevant. Small private companies with no investor reporting obligations may find the framework's capital-markets orientation misaligned with their needs.
Alternative Programs
Frequently Asked Questions
Quick Facts
Certification
English
2011